ADC Therapeutics

ADC Therapeutics is a biotechnology company dedicated to delivering next-generation ADCs for those affected by cancer.
ADC Therapeutics stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

ADC Therapeutics balance sheet

Report period2018 2019 2020 2021 2022Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

ADC Therapeutics cash flows

Report period2018 2019 2020 2021 2022Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

ADC Therapeutics multipliers

Report period2018 2019 2020 2021 2022Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

ADC Therapeutics profitability

Report period2018 2019 2020 2021 2022Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
ADC Therapeutics assets
ADC Therapeutics cash flows

ADC Therapeutics shares

TickerNameTypeNominal valueISINPrice
ADCT:USADC TherapeuticsCommon share-CH0499880968$3.02
ADC Therapeutics news
09.05.2022
ADC Therapeutics' IFRS loss for 3 months of 2022 was $16.661 million, down 3.1 times from $51.527 million in the previous year. Revenues were $46.498 million. The company did not generate revenues a year earlier.
Source: {source} pictogram ir.adctherapeutics.com
Pictogram next
03.03.2022
ADC Therapeutics' GAAP loss for 2021 was $230.026 million, down 6.6% from $246.29 million the previous year. Revenue was $33.917 million; the company earned no revenue last year.
Source: {source} pictogram ir.adctherapeutics.com
Pictogram next
02.11.2021
ADC Therapeutics' IFRS loss for 9M 2021 was $195.645 million, up 2.8% from $190.361 million in the prior year. Revenue was $16.907 million. A year earlier company did not receive revenue.
Source: {source} pictogram ir.adctherapeutics.com
Pictogram next
03.08.2021
ADC Therapeutics' IFRS loss for 6 months of 2021 was $124.096 million, down 27% from $170.033 million in the prior year. Revenues were $3.76 million. A year earlier, the company did not generate revenues.
Source: {source} pictogram ir.adctherapeutics.com
Pictogram next
All ADC Therapeutics news
General information
Company nameADC Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address13625 TECHNOLOGY DRIVE EDEN PRAIRIE MN 55344 9529388080
Mailing address13625 TECHNOLOGY DRIVE EDEN PRAIRIE MN 55344
Websitewww.adctherapeutics.com
Information disclosurewww.sec.gov